Lavendustin A

EGFR inhibitor



BML-EI185-0001	1 mg	143.00 USD

BML-EI185-0005	5 mg	613.00 USD
Do you need bulk/larger quantities?

Replaces Prod. #: ALX-350-007

Cell permeable tyrosine kinase inhibitor with little effect on cAMP-dependent protein kinase (PKA) or protein kinase C (PKC). Potent and selective inhibitor of the EGF receptor tyrosine kinase (IC₅₀=11nM). Binds to a site on the kinase which is distinct from the ATP and peptide substrate binding sites. Inhibits EGF-induced proliferation of cultured human myometrial smooth muscle cells and suppresses VEGF-induced angiogenesis in rats. Effective at 10µM in cultured leech neurons. Also inhibits NMDA-stimulated cGMP production.

Product Details

Alternative Name:	5-Amino-[(N-2,5-dihydroxybenzyl)-N'-2-hydroxybenzyl]salicylic acid, RG14355

Formula:	C₂₁H₁₉NO₆

MW:	381.4

CAS:	125697-92-9

Purity:	≥95% (HPLC)

Appearance:	Off-white to tan solid.

Solubility:	Soluble in DMSO or ethanol.

Shipping:	Ambient Temperature

Long Term Storage:	-20°C

Use/Stability:	Stable for at least 1 year after receipt when stored, as supplied, at -20°C.

Handling:	Protect from oxygen.

Regulatory Status:	RUO - Research Use Only

Please mouse over

Product Literature References

Influence of the tyrosine kinase inhibitors STI571 (Glivec(R)), lavendustin A and genistein on human mast cell line (HMC-1(560)) activation: K. Lober, et al.; J. Cell Biochem. 103, 1076 (2007), Abstract;

Inhibition of atrial wall stretch-induced cardiac hormone secretion by lavendustin A, a potent tyrosine kinase inhibitor: P. Taskinen, et al.; Endocrinology 140, 4198 (1999), Abstract;

Analysis of epidermal growth factor action in human myometrial smooth muscle cells: J.L. Kornyei, et al.; J. Endocrinol. 146, 261 (1995), Abstract;

Solid Phase Synthesis of Lavendustin A and Analogs: J. Green; J. Org. Chem. 60, 4287 (1995),

Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A: D.E. Hu and T.-P.D. Fan; Br. J. Pharmacol. 114, 262 (1995), Abstract;

Tyrosine phosphorylation during synapse formation between identified leech neurons: S. Catarsi, et al.; J. Physiol. 485, 775 (1995), Abstract;

Blockade of nitric oxide synthesis by tyrosine kinase inhibitors in neurones: J. Rodriguez, et al.; Neuropharmacology 33, 1267 (1994), Abstract;

Kinetic analysis of the inhibition of the epidermal growth factor receptor tyrosine kinase by Lavendustin-A and its analogue: C.-Y.J. Hsu, et al.; J. Biol. Chem. 266, 21105 (1991), Abstract;

Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors: T.J. O'Dell, et al.; Nature 353, 558 (1991), Abstract;

Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus: T. Onoda, et al.; J. Nat. Prod. 52, 1252 (1989), Abstract;

Cellular oncogenes and retroviruses: J.M. Bishop; Annu. Rev. Biochem. 52, 301 (1983), Abstract;